Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Onychomycosis Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The market for onychomycosis treatments has experienced robust expansion, projecting an increase from $3.81 billion in 2025 to $4.03 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.7%. This historical growth trajectory has been fueled by factors such as the widespread occurrence of fungal nail infections, a scarcity of sophisticated antifungal medications, a rise in these infections associated with an aging demographic, heightened awareness among dermatological professionals, and the early embrace of topical treatment strategies.
Anticipated for robust expansion over the coming years, the onychomycosis market is projected to reach a valuation of $5.09 billion by 2030, exhibiting a compound annual growth rate of 6.0%. This upward trajectory is fueled by several key factors including a surge in demand for multifaceted treatment approaches, the expanding utilization of teledermatology and remote patient oversight, the continuous advancement of AI-driven diagnostic capabilities, a broader reach within hospital and retail pharmacy networks, and intensified research efforts focused on overcoming antifungal resistance. Concurrently, prominent market developments shaping the forecast period involve a greater embrace of individualized antifungal treatment strategies, the amplified use of teledermatology for both identifying and tracking conditions, the increasing integration of artificial intelligence in diagnosing nail ailments, heightened public consciousness regarding nail health and cleanliness, and the ongoing development of combined oral and topical medication options.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12197&type=smp
Onychomycosis Market Growth Factors: Which Forces Are Supporting Market Expansion?
The escalating prevalence of diabetes is anticipated to be a key driver for the expansion of the onychomycosis market. This chronic condition, characterized by either inadequate insulin production by the pancreas or the body’s inability to effectively use insulin, frequently leads to onychomycosis, a prevalent affliction among diabetic individuals. Effective management of this fungal nail infection, particularly through the prevention and control of its associated complications, directly correlates with the demand for onychomycosis treatments. Illustrating this trend, data from the UK’s National Health Service in June 2024 revealed that in 2023, England recorded an additional 549,000 individuals identified as at risk for type 2 diabetes, elevating the total count of registered pre-diabetes cases to 3,615,330, a notable nearly 20% increase from the 3,065,825 recorded in 2022. Consequently, the growing number of individuals diagnosed with diabetes is fueling the market for onychomycosis solutions.
Onychomycosis Market Segment Performance And Strategic Opportunities
The onychomycosis market covered in this report is segmented –
1) By Type: Distal Subungual Onychomycosis (DSO), White Superficial Onychomycosis (WSO), Proximal Subungual Onychomycosis (PSO), Candida Onychomycosis, Other Types
2) By Treatment: Drug Treatment, Topical Therapy, Other Treatments
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Distal Subungual Onychomycosis (DSO): Dermatophyte Infections, Mixed Infections
2) By White Superficial Onychomycosis (WSO): Trichophyton Mentagrophytes Infections
3) By Proximal Subungual Onychomycosis (PSO): Associated with Nail Psoriasis, Fungal Infections In Immunocompromised Patients
4) By Candida Onychomycosis: Candidal Nail Infections, Mixed Fungal-Candida Infections
5) By Other Types: Total Nail Dystrophy, Secondary Onychomycosis
Onychomycosis Market Industry Trends: What Changes Are Reshaping Demand?
Major players within the onychomycosis sector are actively engaged in creating novel product formulations to solidify their competitive standing. These advancements are crucial for propelling the market forward, as they enhance treatment efficacy and tackle unique issues tied to the ailment. A prime example occurred in February 2024 when Moberg Pharma AB, a pharmaceutical entity headquartered in Sweden, introduced MOB-015. This unique topical treatment utilizes terbinafine in a specialized format, engineered to deliver therapeutic levels precisely to the nail and underlying bed. This targeted approach significantly reduces the potential for systemic side effects often linked with oral terbinafine. MOB-015 has garnered endorsements for countrywide authorization across thirteen European nations and is currently available in Sweden under the brand Terclara. The basis for this authorization rests on two Phase 3 studies, which demonstrated that MOB-015 achieved notably better rates of mycological cure, reaching 76% in contrast to comparative treatments that offered up to 42%, alongside a substantially higher percentage of complete cures and no reported significant adverse events.
Onychomycosis Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the onychomycosis market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sandoz International GmbH, Bausch Health Companies Inc., Perrigo Company plc, Galderma Laboratories LP, Aurobindo Pharma Limited, Cipla Inc., Dr.Reddy’s Laboratories Ltd., Apotex Inc, Lupin Limited, Amneal Pharmaceuticals Inc., Alembic Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Mayne Pharma Group Limited, Wockhardt Ltd., Jubilant Cadista Pharmaceuticals Inc., Moberg Pharma AB, Medimetriks Pharmaceuticals Inc., Blueberry Therapeutics Ltd., Hallux Inc., NovaBiotics Ltd., Zydus Cadila Healthcare Limited.
Access The Complete Onychomycosis Market Report:
https://www.thebusinessresearchcompany.com/report/onychomycosis-global-market-report
Onychomycosis Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the onychomycosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onychomycosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
